Amazon Web Services (AWS) is collaborating with healthcare providers, public health organizations, government agencies, and life science businesses around the globe to support their efforts to cope with the ripple effect of COVID-19. From bench-top to bedside, AWS will help you innovate faster to improve patient outcomes and lower costs.
If you are a startup, or investor that supports startups, speak to us about the programs we have to support healthcare and life sciences startups scale and grow with Amazon and AWS.
Anocca is a privately held medical biotechnology company founded in 2014 and dedicated to establishing an engineered human cell-based discovery, validation and clinical development platform for deciphering T-cell immunity and delivering next generation T-cell therapies. Based in modern facilities near Stockholm, Sweden, Anocca has built up a talented team of almost 50 scientists from 23 different nations.
The fully operational industrialized platform comprises integrated cell biology and genetics modules and is capable of rapidly and systematically identifying and validating antigen/T-cell receptor (TCR) combinations to access a virtually unlimited target space. The platform is underpinned by proprietary, purpose-built IT infrastructure and data handling capability. Alongside, Anocca has established an advanced GMP manufacturing facility to produce cellular therapeutics for clinical use.
Anocca is leveraging its technology platform and manufacturing capabilities to deliver candidates for TCR-modified T-cell therapies in highly segmented patient populations within oncology.
Complementary clinical programs with a fully individualized strategy for targeting the unique aspects of an individual’s cancer cells will also be deployed. Anocca’s technologies will enable the delivery of these transformative cellular therapies for a wide range of cancer types, in almost any individual.
Beyond oncology, Anocca’s platform has been designed for broad use in distinct applications. In particular, this includes the design and deployment of prophylactic vaccines for a wide range of pathogens and for tolerization of autoimmunity.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. https://www.beigene.com/
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
Bone Therapeutics is a listed, clinical-stage, cell therapy company committed to rebuilding lives of patients suffering from debilitating bone and joint conditions. Leveraging its extensive expertise in mesenchymal stromal cells (MSCs), bone physiology and patented manufacturing technology, Bone Therapeutics is developing a commercially ready, allogeneic and off-the-shelf bone cell therapy platform, ALLOB, and a next-generation improved viscosupplement for osteoarthritis pain, JTA-004, which are designed to offer patients and physicians best-in-class treatment options. Currently in Phase II-III clinical development, Bone Therapeutics’ advanced product portfolio targets large orthopaedic conditions with high unmet needs, such as knee osteoarthritis, unhealed fractures and spinal fusion. Leveraging on its allogeneic MSC platform, Bone Therapeutics recently extends the product portfolio into the anti-inflammatory space by the introduction of the new allogeneic product candidate, BT-20. http://www.bonetherapeutics.com
Cognoptix is creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease uniquely detecting amyloid in the lens of the eye. A widely accessible and easy to use diagnostic is particularly urgent and necessary now as new disease modifying therapies (DMTs) are poised to come to the market very soon. These DMTs require amyloid detecting diagnostics that function as companion diagnostics.
Cognoptix’s technology consists of a laser eye scanning device combined with an ophthalmic ointment which specifically identifies Alzheimer’s related amyloid proteins found in the lens of the eye. The technology allows for the amyloid in the lens of the eye to be detected early.
As the company develops its diagnostic platform it has demonstrated success in two proof of concepts clinical studies. The company is planning to go into pivotal studies shortly– Cognoptix’s goal is to provide clinicians with a reliable, inexpensive and widely available test that can be performed quickly and accurately by a general practitioner in an office setting, to enable swift intervention and ongoing monitoring of patients.
It is the mission of Cognoptix to help taking the detection of people at risk of Alzheimer’s mainstream. The company’s stand-out senior management team has built a world-renowned scientific advisory board and senior consultant team, bringing together top experts in the AD, neurocognition, clinical trials and research from across the country. Recently selected to be part of the prestigious Framingham Heart Study, Cognoptix aims to expand collaboration with others in the healthcare diagnostic, biotech, and medical device industries.
The company is raising a $15m Series B for funding of its pivotal trial. Approval of the Sapphire II system for amyloid is expected in 2023.
Euronext is the leading pan-European exchange with global reach and local presence. Operating 6 stock exchanges under one platform, Euronext offers entrepreneurial Life Sciences companies a promising route to further develop their company (scale-up), to obtain financing and realize a partial or full exit.
Immunicum is a clinical-stage biotech developing allogeneic, off-the-shelf cell therapies for solid tumors. Our lead product ilixadencel has now completed a Phase II controlled study in kidney cancer, which showed deeper and more durable tumor responses (including complete responses) and a difference in median survival as compared to control arm. Based on these results, in June 2020, the FDA granted an RMAT Designation, similar to a Breakthrough Therapy Designation. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
MSD is known as Merck in the United States and Canada.
A Legacy of Innovation MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. MSD had sales of more than $39 billion in 2016 and we operate in more than 140 countries.
We recognize that building partnerships is one of our most important jobs. We’re interested in any novel approach with robust, scientific data and significant advantages for patients over current therapies — from discovery to late-stage without regard to therapeutic area or modality.
SphingoTec is a German diagnostic company developing novel test for acute and critical care conditions. SphingoTec’s founder and CEO Dr. Andreas Bergmann previously developed the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™) during his time as Chief Research Officer.at of B.R.A.H.M.S. AG, a diagnostics company he co-founded and successfully sold to Thermo Fisher Scientific in 2009.
SphingoTec’s in-vitro diagnostic tests for acute care settings are addressing diagnostically underserved medical conditions such as sepsis, acute heart failure, circulatory shock, and acute kidney injury. The proprietary biomarkers are patent protected, extensively validated (over 100.000 patients), publicized (over 100 publications) with a large international network of key opinion leaders. Besides developing unique biomarkers, SphingoTec is also a fully integrated commercial provider of complete solutions for innovative rapid diagnostic testing at the point-of-need in acute care settings. Following the acquisition of Nexus Dx (San Diego, CA, U.S.) and its point-of-care platform from Samsung in 2018, SphingoTec has since then continuously expanded its portfolio of rapid diagnostic tests: in addition to commonly used tests for critical care, all novel biomarkers have been implemented on the NexusIB10 platform.
After only one larger VC round in 2018 (investors include HBM and Wellington Partners in Germany) to fund the platform acquisition from Samsung, the company now seeks additional funding to develop the market for its CE-IVD products, run FDA trials and seek FDA clearance for US market access for the novel biomarkers products.
STALICLA is a Biotech Company developing a first-in-class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). STALICLA is using computational systems biology tools technology to characterize correlations between NDD phenotypes, gene expression in relevant molecular pathways and treatment response.
At Syneos Health, we are uniquely positioned to bring into sharp focus the issues that matter most to biotech companies and investors through the breadth and depth of our network, and access to the expertise that the wider Syneos Health organization offers.
We are an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial and consulting, work together to create customer success.
Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. Our clinical, commercial and consulting offerings live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
TOLLYS is developing best in class specific TLR3 agonists in the field of immuno-oncology. TOLLYS was founded in 2015 by senior scientists from the leading European Cancer Research Center of Lyon in France and the Centre Léon Bérard.
They discovered the ability of TLR3 agonists to induce a direct and immunogenic tumor cell death in addition to their immunostimulant properties (activator of antigen presenting cells) and to their ability to induce a switch of the tumoral micro-environment. They postulated that the combination of these 3 actions will lead to an intense activation and recruitment of patient tumor specific cytotoxic T lymphocytes (CTL) in the tumor bed, resulting in anti-tumor effects and in-situ auto vaccination against recurrences.
Former heterogenous dsRNA with TLR3 agonist properties, have demonstrated clinical efficacy in the past in TLR3+ breast cancer patients with a good tolerance but never reached the market due to a lack of product homogeneity. TOLLYS discovered and patented in 2018 a new family of TLR3 agonists, among which TL-532 is the lead candidate, a dsRNA perfectly defined in sequence and length.
TL-532 showed efficacy in preclinical models to induce anti-tumor response and prevention of recurrences with a good tolerability and a synergistic effect with immune checkpoint inhibitors. TOLLYS plans to enter clinical trials with TL-532 in 2021 in Non Muscle Invasive Bladder cancer (NMIBC) unresponsive to BCG treatment, a high medical need indication with a potential for accelerated market approval. TL-532 has a broad indication potential since TLR3 is expressed in a variety of cancers.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a growing commercial business and a significant development pipeline.
A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders we create a clear path for our transformative medicines to reach those that need them.
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is the global leader in gut bacterial culturing, has the world’s leading microbiome Culture Collection, proprietary Reference Genome Database and microbiome AI. The company also has advanced capabilities in translational biology and preclinical development. Microbiotica is exploiting its platform in developing best in class Live Bacterial Therapeutic and Biomarker programs in IBD, Immuno-oncology and C. difficile. It has major collaborations with Genentech/Roche in IBD, University of Adelaide in Ulcerative Colitis, and Cancer Research UK and Cambridge University Hospitals in Immuno-oncology. https://www.microbiotica.com/
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR17. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories.
Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.
Oculis’ novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.
The Company’s leading clinical candidates include OCS-01 and OCS-02:
OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone using Oculis’ proprietary Solubilizing Nanoparticle (SNP) technology. It has successfully completed two Phase 2 clinical trials: in Diabetic Macular Edema (DME) and for treating inflammation and pain following cataract surgery. OCS-01 has the potential to provide the first non-invasive topical treatment option for DME patients and the first once a day, preservative free steroid for inflammation and pain following ocular surgery.
OCS-02 is a novel topical anti-TNF alpha antibody and was in-licensed from Novartis. It has successfully completed two Phase 2 clinical trials in Acute Anterior Uveitis and in Dry Eye Disease.
In addition, Oculis’ formulation discovery focus and capabilities are enabling the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.
Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors. Oculis is headquartered in Lausanne, Switzerland, with research operations in Iceland and France.
RubrYc Therapeutics is discovering biotherapeutics to address unmet clinical needs for cancer and autoimmune disease patients. RubrYc’s platform drives exquisitely epitope-selective antibody discovery, leveraging specific applications of machine learning and computational biology to overcome the constraints of immunodominance. RubrYc's lead program (RTX-003) has demonstrated superior tumor growth inhibition in the Company's American Academy of Cancer Research disclosure last quarter. The Company is actively completing a $10M Convertible Note financing and engaging in Co-Discovery partnerships.
Apogenix is developing innovative biotherapeutics for the treatment of cancer and viral infections. The lead candidate asunercept has demonstrated significant efficacy in glioblastoma and MDS clinical studies. A pivotal phase II/III study for glioblastoma is planned. Two phase II studies in COVID-19 patients will start in Q3/2020.
Apogenix’ scientific team has developed the HERA-ligand technology platform. The first candidate – TRAIL receptor agonist ABBV-621 is out-licensed to Abbvie. Phase I studies are ongoing in solid and hemato-oncological indications.
Brenus Pharma is a french innovative biotech aiming to become leader in allogenic cellular immunotherapy thanks to its unique, patented and scalable technology Stimulated Tumor Cells (STC). Its first therapeutic candidate STC-1010 shows a significant improvement in overall survival in an animal model of colorectal cancer. STC-1010 stimulates patients immune system by fighting immunotolerance, chemoresistance, and the harmful tumor micro-environment which are the three causes of treatment failure. STC-1010 has a rational for use alone and in combination with chemotherapy and immune-checkpoint inhibitors. Brenus Pharma is exploring other indications for STC-1010 and will develop other candidates through its STC platform.
Precirix (formerly Camel-IDS) is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes. The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of single-domain antibodies. The company’s technology platform also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a high therapeutic dose for treatment. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control.
eleva GmbH is opening a realm of unprecedented therapies by harnessing an inconspicuous but incredibly efficient partner: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they downright invite easy, stable engineering and reliable output. We have harnessed its outstanding features to create drug candidates and take them to clinical stages, ready for a bright future.
InterAx Biotech AG has developed a proprietary platform for drug selection and design by combining two complementary capabilities: bench science and mathematical modeling. Our modeling capabilities leverage existing pharmacological knowledge of targets and ligands, but then influence the bench science team. Our bench science generates de novo cellular signaling data to challenge and improve our mathematical models. The two teams work in close tandem to predict in vivo results and guide the design of new molecular entities.
Our focus is on select GPCRs targets where we have deep expertise in systems biology to bring it all together. These targets are aligned with select cancers, autoimmune diseases, and more where the unmet medical need remains high. Our goal is to significantly shorten the time and cost to discover new effective treatments for a wide array of human diseases.
InterAx Biotech AG is a Swiss company and spinoff from the ETH Zurich and the Paul Scherrer Institute (PSI).
Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to the market innovative stem cell-based therapies for regenerative medicine. The first proprietary cellular therapy of Novadip Biosciences is a totally differentiated and 3D osteogenic scaffold-free structure which provide innovative treatments for severe bone healing disorders. Their lead product NVD-001 introduces new principles of guided tissue regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture 3D natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects. In September 2015, NOVADIP has closed EUR 28 million Series A Round with US and Belgian investors to advance his breakthrough cell therapy pipeline.
A venture-backed biotech company with programmes focused on global health and innovation including vaccines against enter fever, Chlamydia trachomatis and Yersinia pestis, the latter being developed with the UK government. The synthetic biology platform, which has been safely tested in 10 clinical trials in 351 volunteers, is also being evaluated as a microbial immunotherapy targeting technology for solid tumours.
Prokarium is based at the London Bioscience Innovation Centre near St Pancras station in Central London. We are always looking to connect with ambitious scientists and advisors within Synthetic Biology/Molecular Biology and Immunology & Oncology.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.
RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults and Aemcolo® for the treatment of travelers’ diarrhea in adults.
RedHill’s key clinical late-stage development programs include:
(i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections (ii) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D (v) RHB-106, an encapsulated bowel preparation (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19.
TOLREMO is a privately held, Basel-based Swiss biotechnology company established in 2017 as a spin-off of ETH Zurich, one of the leading science and technology universities in the world. TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of precision therapies to patients with cancer. Our drug development programs are supported by novel transcriptome-based bioinformatics strategies to guide preclinical translation and clinical development.
Our drug platform is enabled by deep knowledge of assay development for non-mutational drug resistance, phenotypic and biochemical high-throughput screening, complex image analysis algorithms, medicinal chemistry, structure-based drug design, bioinformatics, and unique preclinical models of drug resistance. These capabilities fuel our drug discovery engine and build a strong platform to identify novel drug resistance and transcriptional regulators and develop small molecule therapies against these promising drug targets.
TOLREMO's lead asset TT125 is a preclinical stage, novel transcriptional modulator that is intended to be used as single agent to treat transcriptome-defined subpopulations of patients with blood cancer. It can also be combined with other targeted cancer drugs to prevent the development of drug resistance.
Delta 4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta 4 leverages on a proprietary computational analytics platform, combined with straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering most efficient matching of clinical indications and compound/drug effect. Our R&D process allows a fast track to clinical stage testing; our methodological core is tailored toward precision for increasing probability of success.
Our focus is repositioning of existing drugs for novel indications. With generating IP for such drug-disease combinations we establish a pipeline of clinically and economically attractive indications. Using a unique methodology Delta 4 aims to significantly shorten the development time and increase the probability of success of drug indication screening. Available safety profiles for approved and repositioned drugs further increase likelihood for success in clinical trials.
We recently achieved promising results in two of our drug discovery and development programs. In our lead program, which aims at developing a therapy for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease affecting children and adults, we concluded pre-clinical development with promising results. Patent filing was initiated and we are currently preparing clinical testing of selected drug candidates.
In addition to FSGS, we recently applied our drug discovery platform to COVID-19 to identify existing drugs that may have benefits in this disease. We are currently evaluating a short list of potential COVID-19 therapies pre-clinically and are considering partners to further develop its most promising COVID-19 drug candidates. Patents for the most promising candidates have recently been filed.
GliXogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders which are driven by damage to the neuron’s myelin sheath, such as multiple sclerosis (MS). All approved drugs to date treat MS patients by targeting the immune system and modulating it via various types of mechanisms while unable to address the neurological damage already present at the time of initial diagnosis. Demyelination accounts, at least in part, for the progression of 75% of relapsing-remitting MS patients towards the secondary progressive, more severe form of the disease.
GliXogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease.
MSL Pharma is an early-stage pharma company that performs ideation, analysis and identifies the underlying pathological pathways to determine how to treat diseases.
The Company holds exclusive licenses from the Hebrew and Ben-Gurion Universities of patents an know how for identifying active regions of peptides and proteins, isolating them and developing from them cyclic peptides which are peptidomimetics that are selective and stable. Also, the company has novel delivery technologies to deliver these peptides in the nose-to-brain, trans-dermal, sub-lingual and oral routes of administration. We are developing Somatostatin and Melanocortin analogues, an Adiponectin peptidomimetic and a TLR4 antagonist for the treatment of obesity and metabolic syndrome (type 2 diabetes, dyslipidemia and hypertension). The company has also a novel smart multi-armed linker which can be used for peptide drug conjugates (PDC's), antibody drug conjugates (ADC's) and nanoparticle drug conjugates (NDC's) for Multi-Targeted drug Delivery. Our linker can bind up to three payloads and releases the payloads only in the tumor cells. The payloads can be chemotherapeutic drugs or fluorescent for diagnostics.
We have proved that using two or three drugs is more potent in killing tumor cells than one drug and also less drug resistance develops. We also have technologies to synthesize peptides which will bind to certain receptors which are overexpressed in certain tumors, in order to use them for PDC's.
We are starting with developing diagnostics and treatments for pancreatic and ovarian cancers. These cancers are located deep in the abdomen and as of today they are usually diagnosed at a late stage (stage 4) when it is already too late for the patient. We will screen populations which are at risk like people which are genetically predisposed, alcohol drinkers and meat eaters and diagnose them at an early stage when the disease is still totally curable.
Molsid is an innovative biotech company developing a new generation of fluorogenic molecular probes. Our SmartID technology detects enzymatic activity in living cells in an unprecedented way: fast, easy, precise, and reliable.
Fast, precise, easy, and reliable detection of enzymatic activity in living cells is a key factor for industrial competitiveness and the performance of the public health system, in areas such as rapid pathogen diagnostics, the detection of antibiotic resistance and food quality control.
In the past 50 years, the rise of modern flow cytometry and high-resolution microscopy has revolutionized biological single-cell analysis. However, the development of high-performance fluorogenic probes has lagged behind for several decades.
This lack is a major barrier for the development of many high-potential technologies such as Directed Evolution and High-Throughput Flow Cytometry. The absence of such probes creates a unique opportunity in the biotech market for a high-performance probe technology.
"ThermoPharma is an innovative pre-clinical stage company targeting the metastatic process of solid, aggressive cancer tumors. We have demonstrated the efficacy in triple-negative breast cancer mice xenograft; other solid tumor models like colon cancer and other indications underway.
Our patented lead compound is first in class small molecular Carbonic Anhydrase IX (CA IX) targeting the reduction of hypoxia in the tumor microenvironment. CAIX binds to receptors responsible for increasing the hypoxic microenvironment of the solid tumors and prevents metastatic spread.
Our compound is designed to be used as a combination therapy and potentially increases response to immunotherapy
Invested to time >$7M. Raising Series A: $1.5 - $2 million to finish IND submission and start PH1 trial. Potential return for the investors: > 10x
We solve problems in healthcare using AI and our vision is to improve healthcare for ALL using technology. Our free, patient-facing product helps patients search for, access and understand clinical trials. Our AI-powered platform provides easy access to clinical trial information, with modules for patients, physicians and investigators, and providing support across the treatment journey. Our team has a 50/50 gender balance and includes data scientists, technologists and scientists who all share deep expertise in healthcare. Since our foundation, we have received support and/or funding from Google for Startups, NVIDIA, Almirall’s Digital Garden, Future Perfect, RuhrLAB Building Bridges, and EIT Health.
BestHealth4U is an R&D company, specialized in developing new and advanced material solutions for skin-interacting medical devices. Our role is to investigate, analyse and identify the needs of patients and the healthcare market in order to develop innovative technologies that answer and provide better solutions for the medical field.
The vision of BOCAhealth is to improve the quality of life and to reduce the mortality of chronic ill patients at high risk such as chronic kidney disease (CKD), chronic heart failure patients (CHF) and elderly patients, via optimal fluid management by utilizing innovative sensors and AI technology.
CRIAM is a med-tech startup born in 2016 focused on the Point-of-Care blood diagnostic segment. Recently accelerated by HAX/SOSV, the world’s first and largest hardware accelerator from Silicon Valley, in a program sponsored by Johnson & Johnson Innovation. It won the Top EU 50 most Innovative Company Award from the EU.
DROPLITE is a biotechnology company introducing a novel in-vitro smart diagnostics device, that in solely 10 min delivers accurate test results on the detection and quantification of specific diseases and health conditions, based on an immunoassay biochemical testing technique. Our primary goal is to bring an on-site testing solution to doctors and patients that is - faster, automated and more affordable than the established, slow and complex laboratory tests. Our patent-pending optical sensing technology combined with nanotechnology and dedicated immunoassay chemistry, is designed for versatility, reliability, robustness and automation. Our main market is the in-vitro fertility sector, where our novel solution detects and quantifies sexual hormones in blood in a matter of minutes, in particular estradiol, a critical hormone monitored in every fertility treatment cycle. In addition to fertility, we are targeting an additional beachhead market: veterinary - rapid detection of pet diseases. The inclusion of this market is purely strategic, since it allows us to start commercialization earlier, given its lower legislation and certification barrier, when compared to human health. Moreover, the vet market is quite big and growing, allowing us to start generating revenue, that will then support the development and market entry of the human health applications. DROPLITE has achieved central-lab quality results, reducing by 10-fold the test times and sample volume, using our reader-cartridge prototype. Our goal is to provide a test solution to diagnose and start the treatment in the same medical appointment, without the need of a laboratory, long waiting times and second visits to the clinic/hospital. This concept applies to the fertility sector, veterinary and other human markets we are exploring.
Evora Biosciences is a translational research biotech, leveraging strong IP on sizeable and clearly defined unmet medical needs, with a focus on extracellular vesicles (aka exosomes) -based therapies.
Our lead candidate is EVOGEX, a treatment for digestive fistula. EVOGEX is a breakthrough, scalable and cell-free version of regenerative cell therapies for digestive fistula. EVOGEX adresses a market estimated at €2bn annual sales, with a clearly defined spot for a new and improved standard of care.
HiQ-Nano is a start-up company from the Italian Institute of Technology - IIT, born with the goal to develop innovative ideas and out-of-the-box approaches in the field of point-of-care diagnostics, home testing, and colorimetric assays.
Indicate Solutions S.L. grew out of the INDICATE detection project which was started in 2013 by Charles Lawrie of Biodonostia, Luis Liz- Marzán and Marek Gzelczak of CIC biomaGUNE in San Sebastián, Spain.
The concept behind the INDICATE detection project is simple; to create a rapid nucleic acid test (NAT) as a single-use handheld POC device.
In response to the global COVID-19 crisis, Indicate Solutions has conceived a Sars2 rapid test. Filled EPO patent (EP 20382499.0).
Indicate Solutions’ instant test with results available in <30 minutes could be used to screen more frequently resulting in a rapid identification and isolation of infected populations.
We are working on a rapid, economic, reliable and easy to use diagnostic tests to detect biomarkers of SARS CoV 2 whenever and wherever needed worldwide.
Kyme NanoImaging Srl develops and produces innovative nanotech formulations for Medical Imaging.
The formulations are able to increase the efficacy of clinically approved contrast agents for magnetic resonance imaging (MRI) and, at the same time, reduce their toxicity. This is obtained by combining contrast agents with biomaterials using patented nanotechnologies.
The obtained products make visible anatomical details otherwise not appreciable, ensuring better diagnosis and reduced side effects.
MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.
MOWOOT offers a CE certified (Med.Dev. class IIa), IP protected, clinically validated and award-winning technology: the first Intermittent Colonic Exo-peristalsis (ICE) device on the market handling a large unmet need for patients with Neurogenic-Bowel-Disorders (NBD), Idiopathic Chronic Constipation (ICC) and Opioid-Induced-Constipation (OIC).
The Global Market for the indication "chronic constipation" alone has an annual worth of US$ 12.58 bn, with a healthy CAGR of 7.1%, estimated to reach US$ 22,93 bn by 2025.
Nia Health develops an innovative platform for dermatological software in the field of dermatology.
Illness that directly affects the skin is the fourth most frequent cause of all human disease. Almost one-third of the world’s population is affected. Dermatological conditions are therefore a major reason for seeking medical help in all societies. Patients are often severely restricted in their lifestyles due to skin diseases. The disease is often visible to others, which can lead to additional psychological stress for those affected. Patients especially young parents of affected children (in case of atopic dermatitis 50% of all patients) are characterized by a particularly high level of suffering.
Nia Health supports patients and their relatives in their daily dealings with skin diseases by offering them a holistic, digital support. The medically validated content and personalized functions of Nia Health help people to actively shape their health and improve their quality of life.
PatchAi Srl is an italian innovative start-up borned in August 2018 aiming to transform clinical research by virtue of focus on patient centricity and forefront digital technologies through digital health solutions dedicated to safer, faster and affordable medical product development for the betterment of patients’ lives. PatchAi develops end to end patient engagement solutions to empower the person throughout clinical studies and care pathways.
Plusimple is a Plug&Play digital solution aimed to facilitate communication and engagement between all the health stakeholders with a secure and scalable technology that generates a fast growing health network.
WhiteLab Genomics is specialised in developing solutions and applications in order to accelerate the development of innovative therapies, such as cell and gene therapies.
We develop a unique solution using machine learning to help our customers develop their innovative therapies faster and at a lower cost. Our solution is 100% solution and adresses the needs of academic laboratories, biotech and pharma companies.
Our team is composed of expert in the field of genetic engineering, artificial intelligence and computational biology.
Created in 2019, we have already been awarded several European and French awards.
We are part of the Genopole, one of Europe largest Biocluster - Station F, largest European Start-Up campus and among the most 40 promising start-up on the campus, and part of the Genetic Engineering of the National Institue of Standard and Technologies in the USA.